Steffen Schubert

Steffen Schubert has an extensive work experience in various industries. Steffen started their career as an Assistant to Chorus Master at Deutsche Oper Berlin in 1992. Steffen then worked as an Opera Coach at Deutsche Oper Berlin from 1996 to 1998. Following that, they served as a Chorus Master/Conductor at Salzburger Landestheater from 1998 to 2000. Steffen later pursued their education at Freie Universität Berlin as a Graduate Student from 2003 to 2006. Steffen then joined Dana-Farber Cancer Institute, Harvard Medical School as a Postdoctoral fellow from 2006 to 2008.

In 2009, Steffen Schubert took on the role of Senior Group Leader at Cenix Bioscience. Steffen later became the Director of Research and Development at the same company from 2014 to 2015. Concurrently, they also served as the Artistic Director at Ernst Senff Chor from 2009 onwards.

From 2015, Steffen Schubert transitioned into the pharmaceutical industry, working at Silence Therapeutics plc. Steffen first held the position of Group Leader mRNA from 2015 to 2016. Steffen then served as the Head of in vitro Pharmacology from 2016 to 2018. Following that, they were appointed as the Head of Drug Discovery at Silence Therapeutics from 2018 to 2021. Currently, they hold the position of Vice President Drug Discovery at the same company, starting in January 2021.

Steffen Schubert began their education in 1990 at Hochschule der Künste Berlin, where they pursued a Diploma in Conducting. Steffen successfully completed their diploma in 1994. Following this, from 1994 to 2002, they attended Freie Universität Berlin, specializing in Biochemistry. During their time at the university, they obtained a Diploma (Master) degree in Biochemistry.